[1] Vivarelli M,Massella L,Ruggiero B,et.al. Minimal Change Disease[J]. Clin J Am SocNephrol. 2017,12(2):332-345. [2] Rovin B H,Caster D J,Cattran D C,et al.Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J].Kidney Int, 2019,95(2):281-295. [3] Korbet S M,Whittier W L.Management of Adult Minimal Change Disease[J]. Clinical Journal of the American Society of Nephrology,2019,14(6):911-913. [4] Cattran D C,Feehally J,Cook H T,et al.Kidney Disease Improving Global Outcomes Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulon- phritis[J]. Kidney International Supplements,2012, 2(2): 139-274. [5] Hogan J,Radhakrishnan J.The treatment of minimal change disease in adults[J]. J Am Soc Nephrol,2013,24(5): 702-711. [6] Palmer S C,Nand K,Strippoli G F M. Interventions for minimal change disease in adults with nephrotic syndrome[J]. Cochrane Database Syst Rev, 2008,(1):2-10. [7] Hwang Y G,Saag K.The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies[J]. Neuroimmunomodulation,2015,22(1-2):72-82. [8] Ke Q,He F,Lu L,et al.The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis[J]. Neuro- muscul Disord,2015,25(12):955-957. [9] Finsterer J.Primary periodic paralyses[J]. Acta Neurol Scand, 2008,117(3):145-158. [10] Lin S H,Huang C L.Mechanism of thyrotoxic periodic paralysis[J]. Journal of the American Society of Nephrology, 2012, 23(6):985-988. [11] Arzel-Hézode M,McGoey S,Sternberg D,et al.Glucocorticoids may trigger attacks in several types of periodic paralysis[J].Neuromuscul disord,2009,19(3): 217-219. [12] Poulin H,Gosselin-Badaroudine P,Vicart S,et al.Substitutions of the S4DIV R2 residue (R1451) in Na V 1.4 lead to complex forms of paramyotonia congenita and periodic paralyses[J]. Sci Rep, 2018 ,8(1):2041. [13] 王兆平, 高峰, 刘洁一,等.糖皮质激素低钾性麻痹与原发性低钾性麻痹比较研究[J].河北医药, 2015, 37(6):877-879. [14] Levitt J O.Practical aspects in the management of hypokalemic periodic paralysis[J]. Journal of translational medicine, 2008,6(1):1-8. [15] Weber F, Jurkat-Rott K, Lehmann-Horn F. Hyperkalemic periodic paralysis[J/OL].(2003-07-18)[2016-01-28]. https://www.ncbi.nlm.nih.gov/books/NBK1496/. [16] Kasper D,Fauci A,Hauser S,el al. Harrison's Principles of Internal Medicine[M]. 19th ed. New York: McGraw- Hill Education,2015. [17] Teagarden C M, Picardo C W.Betamethasone-induced hypokalemic periodic paralysis in pregnancy[J]. Obstetrics & Gynecology, 2011, 117(2): 433-435. [18] Lapie P,Lory P,Fontaine B.Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel[J]. Neurom- uscul Disord, 1997,7(4):234-400. [19] Lewis K L,Malouff T D,Kesler A M,el al. Hypokalemic Periodic Paralysis- the importance of patient education[J]. Rom J Intern Med ,2019,(1):1-8. [20] 陈瑶. 泼尼松致30例不良反应文献分析[J].中国药物警戒,2010,7(10):626-628. [21] 张凯, 童荣, 倪娟, 等.1次静滴地塞米松诱发低钾性麻痹例[J].西南国防医药,2017,27(8):898-898. [22] 钟林清, 许名远, 许慈萱, 等.宁德地区低钾型周期性麻痹152例诱因分析[J].中国实用医药, 2015, 10(8):114-115. [23] 司继刚. 地塞米松注射液临床应用安全性分析评价[J]. 中国药学杂志,2016,51(22):1972-1975. [24] 李志金, 杨赞章, 李善学.甲泼尼龙致低钾性麻痹2例[J].医药导报, 2015,34(8):1117-1118. [25] 张永兰, 程岩, 王桂萍, 等.突发性聋患者口服甲泼尼龙致低钾麻痹一例[J].中华耳鼻咽喉头颈外科杂志, 2016, 51(10):783-784. [26] 李群,胡怀岭,刘尚,等.低钾血症118 例心电图分析[J]. 岭南急诊医学杂志,2014,19(3): 220-221. |